Hematopoietic growth factors and autologous or allogeneic stem cell transplantation;Utilisation des facteurs de croissance hématopoïétiques et transplantation de cellules souches d'origine autologue ou allogénique

Bulletin du Cancer

Volumn 93, Issue 5, 2006, Pages 473-482

  Bay, Jacques Olivier ^a   Peffault De Latour, Régis ^b   Tournilhac, Olivier ^c   Choufi, Bachra ^a   Chassagne, Jacques ^a  

^a CENTRE JEAN PERRIN   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c HÔTEL DIEU   (France)

Author keywords

Allogeneic transplantation; Autologous transplantation; Growth factors; Leucapheresis

Indexed keywords

HEMOPOIETIC GROWTH FACTOR; INTERLEUKIN 3; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ERYTHROCYTE TRANSFUSION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; INFECTION COMPLICATION; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL; REVIEW; STEM CELL MOBILIZATION; CHEMICALLY INDUCED DISORDER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKAPHERESIS; METHODOLOGY;

ANTINEOPLASTIC AGENTS; ERYTHROPOIETIN; FILGRASTIM; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HEMATOPOIETIC CELL GROWTH FACTORS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKAPHERESIS; NEUTROPENIA; RECOMBINANT PROTEINS;

EID: 33745294001     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325: 164-70.
2. Trillet-Lenoir V, Arpin D, Brune J. Optimal delivery of dose in cancer chemotherapy with the support of haematopoietic growth factors. Eur J Cancer 1993; 29A (suppl. 5): S14-6.
3. Borg C, Trillet-Lenoir V. Les principes généraux de l'effet dose. Bull Cancer 2001; 88: 833-4.
4. Goodman JW, Hodgson GS. Evidence for stem cells in the peripheral blood of mice. Blood 1962; 19: 702-14.
5. Goldman JM, Th'ng KH, Park DS, Spiers AS, Lowenthal RM, Ruutu T. Collection, cryopreservation and subsequent viability of haemopoietic stem cells intended for treatment of chronic granulocytic leukaemia in blast-cell transformation. Br J Haematol 1978; 40: 185-95.
6. Gianni AM, Siena S, Bregni M, Tarella C, Stern AC, Pileri A, et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; ii: 580-5.
7. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-7.
8. Nademanee A, Sniecinski I, Schmidt GM, Dagis AC, O'Donnell MR, Snyder DS, et al. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. J Clin Oncol 1994; 12: 2176-86.
9. Gratwohl A, Schmid O, Baldomero H, Horisberger B, Urbano-Ispizua A, Accreditation Committee of the European Group for Blood and Marrow Transplantation. Haematopoietic stem cell transplantation (HSCT) in Europe 2002. Changes in indication and impact of team density. A report of the EBMT activity survey. Bone Marrow Transplant 2004; 34: 855-75.
10. Mohty M, Kuentz M, Michallet M, Bourhis JH, Milpied N, Sutton L, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood 2002; 100: 3128-34.
11. Remberger M, Ringden O, Blau IW, Ottinger H, Kremens B, Kiehl MG, et al. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 2001; 98: 1739-45.
12. Remberger M, Beelen DW, Fauser A, Basara N, Basu O, Ringden O. Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood 2005; 105: 548-51.
13. Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000; 5: 3702-9.
14. Horan JT, Liesveld JL, Fernandez ID, Lyman GH, Phillips GL, Lerner NB, et al. Survival after HLA-identical allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies: meta-analysis of randomized controlled trials. Bone Marrow Transplant 2003; 32: 293-8.
15. Smith TJ. Economic analysis of the clinical uses of the colony-stimulating factors. Curr Opin Hematol 1996; 3: 175-9.
16. Le Corroller AG, Fortanier C, Faucher C, Biaise D, Moatti JP. L'évaluation économique de l'autogreffe de cellules souches hématopoïétiques périphériques. Bull Cancer 2001; 88: 893-9.
17. Van Agthoven M, Vellenga E, Fibbe WE, Kingma T, Uyl-de Groot CA. Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease. a prospective randomised trial. Eur J Cancer 2001; 37: 1781-9.
18. Vicent MG, Madero L, Chamorro L, Madero R, Diaz MA. Comparative cost analysis of autologous peripheral blood progenitor cell and bone marrow transplantation in pediatric patients with malignancies. Haematologica 2001; 86: 1087-94.
19. Dix SP, Geller RB. High-dose chemotherapy with autologous stem cell rescue in the outpatient setting. Oncol 2000; 14: 171-85.
20. Brugger W, Bross KJ, Glatt M, Weber F, Mertelsmann R, Kanz L. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636-40.
21. Passos-Coelho JL, Ross AA, Kahn DJ, Moss TJ, Davis JM, Huelskamp AM, et al. Similar breast cancer cell contamination of single-day peripheral-blood progenitor-cell collections obtained after priming with hematopoietic growth factor alone or after cyclophosphamide followed by growth factor. J Clin Oncol 1996; 14: 2569-75.
22. Rill DR, Santana VM, Roberts WM, Nilson T, Bowman LC, Krance RA, et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994; 84: 380-3.
23. Deisseroth AB, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D, et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068-76.
24. Douay L. La thérapie cellulaire pour l'intensification thérapeutique en onco-hématologie: manipulation des greffons de cellules souches hématopoïétiques. Bull Cancer 2001; 88: 826-32.
25. Patriarca F, Sacco C, Sperotto A, Geromin A, Damiani D, Fili C, et al. Prognostic significance of the detection of tumour cells in peripheral blood stem cell collections in stage II and III breast cancer patients treated with high-dose therapy. Bone Marrow Transplant 2003; 31: 789-94.
26. Quesenberry PJ, Colvin G, Abedi M. Perspective: fundamental and clinical concepts on stem cell homing and engraftment: a journey to niches and beyond. Exp Hematol 2005; 33: 9-19.
27. Dercksen MW, Gerritsen WR, Rodenhuis S, Dirkson MK, Slaper-Cortenbach IC, Schaasberg WP, et al. Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation. Blood 1995; 85: 3313-9.
28. Katayama Y, Hidalgo A, Peired A, Frenette PS. Integrin alpha4beta7 and its counterreceptor MAdCAM-1 contribute to hematopoietic progenitor recruitment into bone marrow following transplantation. Blood 2004; 104: 2020-6.
29. Papayannopoulou T, Craddock C, Nakamoto B, Priestley GV, Wolf NS. The VLA4/VCAM-1 adhesion pathway defines contrasting mechanisms of lodgement of transplanted murine hemopoietic progenitors between bone marrow and spleen. Proc Natl Acad Sci USA 1995; 92: 9647-51.
30. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380: 439-42.
31. Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nat 1998; 393: 591-4.
32. Yong KL, Watts M, Shaun Thomas N, Sullivan A, Ings S, Linch DC. Transmigration of CD34+ cells across specialized and nonspecialized endothelium requires prior activation by growth factors and is mediated by PECAM-1 (CD31). Blood 1998; 91: 1196-205.
33. Cottler-Fox MH, Lapidot T, Petit I, Kollet O, DiPersio JF, Link D, et al. Stem cell mobilization. Hematol (Am Soc Hematol Educ Program) 2003: 419-37.
34. Tournilhac O, Cazin B, Lepretre S, Divine M, Maloum K, Delmer A, et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004; 103: 363-5.
35. Roche H, Viens P, Biron P, Lotz JP, Asselain B, Pegase Group. High-dose chemotherapy for breast cancer: the French PEGASE experience. Cancer Control 2003; 10: 42-7.
36. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002; 99: 731-5.
37. Pavone V, Gaudio F, Guarini A, Perrone T, Zonno A, Curci P, et al. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 29: 285-90.
38. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-6.
39. Gomez-Espuch J, Moraleda JM, Ortuno F, Lozano ML, Ayala F, Vallejo C, et al. Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotherapeutic agent, associated with rhG-CSF. Bone Marrow Transplant 2000; 25: 231-5.
40. Legros M, Dauplat J, Fleury J, Cure H, Suzanne F, Chassagne J, et al. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results. J Clin Oncol 1997; 15: 1302-8.
41. Andre M, Baudoux E, Bron D, Canon JL, D'Hondt V, Fassotte MF, et al. Phase III randomized study comparing 5 or 10 microg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies. Transfusion 2003; 43: 50-7.
42. Zeller W, Gutensohn K, Stockschlader M, Dierlamm J, Kroger N, Koehne G, et al. Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of the testis. Bone Marrow Transplant 1996; 17: 709-13.
43. Engelhardt M, Bertz H, Afting M, Waller CF, Finke J. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34 (+) immunoselection. J Clin Oncol 1999; 17: 2160-72.
44. Kroger N, Zeller W, Hassan HT, Kruger W, Gutensohn K, Loliger C, et al. Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 × 5 microg/kg) compared to a single dose (1 × 10 microg/kg). Bone Marrow Transplant 1999; 23: 125-9.
45. Kroger N, Renges H, Kruger W, Gutensohn K, Loliger C, Carrero I, et al. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. Br J Haematol 2000; 111: 761-5.
46. Narayanasami U, Kanteti R, Morelli J, Klekar A, Al-Olama A, Kearing C, et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001; 98: 2059-64.
47. Martinez C, Urbano-Ispizua A, Marin P, Merino A, Rovira M, Carreras E, et al. Efficacy and toxicity of a high-dose G-CSF schedule for peripheral blood progenitor cell mobilization in healthy donors. Bone Marrow Transplant 1999; 24: 1273-8.
48. Anderlini P, Donato M, Lauppe MJ, Huh YO, Martin TG, Chan KW, et al. A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors. Br J Haematol 2000; 109: 770-2.
49. Arat M, Arslan O, Gurman G, Dalva K, Ozcan M, Ugur A, et al. The impact of granulocyte colony stimulating factor at content of donor lymphocytes collected for cellular immunotherapy. Transfus Apheresis Sci 2004; 30: 9-15.
50. Bhatt V, Saleem A. Review: Drug-induced neutropenia: pathophysiology, clinical features, and management. Ann Clin Lab Sci 2004; 34: 131-7.
51. Isidorins A, Tani M, Bonifazi F, Zinzani P, Curti A, Motta MR, et al. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. Haematologica 2005; 90: 225-31.
52. Steidl U, Fenk R, Bruns I, Neumann F, Kondakci M, Hoyer B, et al. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2005; 35: 33-6.
53. Weaver CH, Schulman KA, Wilson-Relyea B, Birch R, West W, Buckner CD. Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. J Clin Oncol 2000; 18: 43-53.
54. Philip I, Jung J, Thiebaut A, Bay JO, Raus N, Clapisson G, et al. Result of a multicentric randomised study comparing low doses of hemopoietic growth factors for PBSC mobilisation in autologous transplantation: 3 days of GM-CSF and 2 days of G-CSF versus 5 days of G-CSF. Bone Marrow Transplant xxxx; 29: 231 (abst. 819).
55. Koc ON, Gerson SL, Cooper BW, Laughlin M, Meyerson H, Kutteh L, et al. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. J Clin Oncol 2000; 18: 1824-30.
56. Nowrousian MR, WaschkeS, Bojko P, Welt A, Schuett P, Ebeling P, et al. Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patients. Ann Oncol 2003; 14 (suppl. 1): i29-36.
57. Benboubker L, Cartron G, Roingeard F, Delain M, Degenne M, Linassier C, et al. Long-term marrow reconstitutive ability of autologous grafts in lymphoma patients using peripheral blood mobilized with granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor compared to bone marrow. Exp Hematol 2003; 31: 89-97.
58. Zumberg MS, Leather HL, Nejame C, Meyer C, Wingard JR. GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation. Cytotherapy 2002; 4: 531-8.
59. Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, Olujohungbe AB, et al. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Biol Blood Marrow Transplant 2004; 10: 395-404.
60. Legros M, Fleury J, Bay JO, Choufi B, Basile M, Condat P, et al. RhGM-CSF versus placebo following rhGM-CSF-mobilized PBPC transplantation: a phase III double-blind randomized trial. Bone Marrow Transplant 1997; 19: 209-13.
61. Lane TA, Ho AD, Bashey A, Peterson S, Young D, Law P. Mobilization of blood-derived stem and progenitor cells in normal subjects by granulocyte-macrophage- and granulocyte-colony-stimulating factors. Transfusion 1999; 39: 39-47.
62. Sohn SK, Kim JG, Seo KW, Chae YS, Jung JT, Suh JS, et al. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2002; 30: 81-6.
63. Pettengell R, Woll PJ, Chang J, Coutinho L, Testa NG, Crowther D. Effects of erythropoietin on mobilisation of haemopoietic progenitor cells. Bone Marrow Transplant 1994; 14: 125-30.
64. Olivieri A, Scortechini I, Capelli D, Montanari M, Lucesole M, Gini G, et al. Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders. Bone Marrow Transplant 2004; 34: 693-702.
65. Waller CF, von Lintig F, Daskalakis A, Musahl V, Lange W. Mobilization of peripheral blood progenitor cells in patients with breast cancer: a prospective randomized trial comparing rhG-CSF with the combination of rhG-CSF plus rhEpo after VIP-E chemotherapy. Bone Marrow Transplant 1999; 24: 19-24.
66. Geissler K, Peschel C, Niederwieser D, Strobl H, Goldschmitt J, Ohler L, et al. Potentiation of granulocyte colony-stimulating factor-induced mobilization of circulating progenitor cells by seven-day pretreatment with interleukin-3. Blood 1996; 87: 2732-9.
67. Lemoli RM, Rosti G, Visani G, Gherlinzoni F, Miggiano MC, Fortuna A, et al. Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma. J Clin Oncol 1996; 14: 3018-25.
68. Stiff P, Gingrich R, Luger S, Wyres MR, Brown RA, LeMaistre CF, et al. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant 2000; 26: 471-81.
69. Facon T, Harousseau JL, Maloisel F, Attal M, Odriozola J, Alegre A, et al. Stem cell factor in combination with filgrasrim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial. Blood 1999; 94: 1218-25.
70. Shpall EJ, Wheeler CA, Turner SA, Yanovich S, Brown RA, Pecora AL, et al. A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood 1999; 93: 2491-501.
71. Prosper F, Sola C, Hornedo J, Arbona C, Menendez P, Orfao A, et al. Mobilization of peripheral blood progenitor cells with a combination of cyclophosphamide, r-metHuSCF and filgrastim in patients with breast cancer previously treated with chemotherapy. Leukemia 2003; 17: 437-41.
72. Tepler I, Elias L, Smith JW, Hussein M, Rosen G, Chang AY, et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996; 87: 3607-14.
73. Bolwell B, Vredenburgh J, Overmoyer B, Gilbert C, Chap L, Menchaca DM, et al. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation. Bone Marrow Transplant 2000; 26: 141-5.
74. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, Broxmeyer HE, Kudelka AP, Freedman RS, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 2000; 132: 364-8.
75. Goldman SC, Bracho F, Davenport V, Slack R, Areman E, Shen V, et al. Feasibility study of IL-11 and granulocyte colony-stimulating factor after myelosuppressive chemotherapy to mobilize peripheral blood stem cells from heavily pretreated patients. J Pediatr Hematol Oncol 2001; 23: 300-5.
76. Gajewski JL, Rondon G, Donato ML, Anderlini P, Korbling M, Ippoliti C, et al. Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization. Biol Blood Marrow Transplant 2002; 8: 550-6.
77. Gisselbrecht C, Prentice HG, Bacigalupo A, Biron P, Milpied N, Rubie H, et al. Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation. Lancet 1994; 343: 696-700.
78. Stahel RA, Jost LM, Cerny T, Pichert G, Honegger H, Tobler A, et al. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol 1994; 12: 1931-8.
79. Bolwell B, Goormastic M, Dannley R, Andresen S, Overmoyer B, Mendez Z, et al. G-CSF post-autologous progenitor cell transplantation: a randomized study of 5, 10, and 16 micrograms/kg/day. Bone Marrow Transplant 1997; 19: 215-9.
80. Bolwell BJ, Pohlman B, Andresen S, Kalaycio M, Goormastic M, Wise K, et al. Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial. Bone Marrow Transplant 1998; 21: 369-73.
81. Faucher C, Le Corroller AG, Chabannon C, Novakovitch G, Manonni P, Moatti JP, et al. Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study. Bone Marrow Transplant 1996; 17: 533-6.
82. Cetkovsky P, Koza V, Jindra P, Skopek P, Svojgrova M. Individual criteria could be optimal for starting G-CSF application after autologous stem cell transplantation. Bone Marrow Transplant 1997; 20: 639-41.
83. Bence-Bruckler I, Bredeson C, Atkins H, McDiarmid S, Hamelin L, Hopkins H, et al. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 versus day 7 post-autologous stem cell transplantation. Bone Marrow Transplant 1998; 22: 965-9.
84. Cortelazzo S, Viero P, Bellavita P, Rossi A, Buelli M, Borleri GM, et al. Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 935-41.
85. Lee SJ, Weller E, Alyea EP, Ritz J, Soiffer RJ. Efficacy and costs of granulocyte colony-stimulating factor in allogeneic T-cell depleted bone marrow transplantation. Blood 1998; 92: 2725-9.
86. Bishop MR, Tarantolo SR, Geller RB, Lynch JC, Bierman PJ, Pavletic ZS, et al. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 2000; 96: 80-5.
87. Franzke A, Piao W, Lauber J, Gatzlaff P, Konecke C, Hansen W, et al. G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases. Blood 2003; 102: 734-9.
88. Ringden O, Labopin M, Gorin NC, Le Blanc K, Rocha V, Gluckman E, et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2004; 22: 416-23.
89. Mohty M, Faucher C, Blaise D. Graft-versus-host-disease and granulocyte colony-stimulating factor administration after allogeneic stem cell transplantation. Leukemia 2005; (in press).
90. Bishop MR, Anderson JR, Jackson JD, Bierman PJ, Reed EC, Vose JM, et al. High-dose therapy and peripheral blood progenitor cell transplantation: effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft. Blood 1994; 83: 610-6.
91. Bolwell BJ, Goormastic M, Yanssens T, Dannley R, Baucco P, Fishleder A. Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and for enhancing marrow recovery after autologous bone marrow transplant. Bone Marrow Transplant 1994; 14: 913-8.
92. Recchia F, Accorsi P, Bonfini T, De Filippis S, Grimaldi M, Corrao G, et al. Randomized trial of sequential administration of G-CSF and GM-CSF vs. G-CSF alone following peripheral blood progenitor cell autograft in solid tumors.J Interferon Cytokine Res 2000; 20: 171-7.
93. Nemunaitis J, Rosenfeld CS, Ash R, Freedman MH, Deeg HJ, Appelbaum F, et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15: 949-54.
94. Link H, Boogaerts MA, Fauser AA, Slavin S, Reiffers J, Gorin NC, et al. A controlled trial of recombinant human erythropoietin after bone marrow transplantation. Blood 1994; 84: 3327-35.
95. Chao NJ, Schriber JR, Long GD, Negrin RS, Catolico M, Brown BW, et al. A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Blood 1994; 83: 2823-8.
96. Vey N, Damaj G, Faucher C, Bay JO, Michallet M, Braud AC, et al. Impact of epoetin alfa on erythroid reconstitution following autologous stem cell transplantation: results of a pilot study. Bone Marrow Transplant 2002; 31: S102; (abst. 479).
97. Klaesson S, Ringden O, Ljungman P, Lonnqvist B, Wennberg L. Reduced blood transfusions requirements after allogeneic bone marrow Transplantation: results of a randomised, double-blind study with high-dose erythropoietin. Bone Marrow Transplant 1994; 13: 397-402.
98. Borbolla JR, Lopez-Hernandez MA, De Diego J, Gonzalez-Avante M, Trueba E, Collados MT. Use of interleukin-11 after autologous stem cell transplant: report of three cases and a very brief review of the literature. Haematologica 2001; 86: 891-2.
99. Nash RA, Kurzrock R, DiPersio J, Vose J, Linker C, Maharaj D, et al. A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2000; 6: 25-34.
100. Archimbaud E, Ottmann OG, Yin JA, Lechner K, Dombret H, Sanz MA, et al. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood 1999; 94: 3694-701.
101. Spaeth D, Casadevall N, Daouphars M, Marchal C, Marec-Berard P, Fabre N, et al. Summary version of the Standards, Options and Recommendations for the use of recombinant erythropoietin (epoietin-alpha and beta, darbepoietin-alpha, EPO) in the management of anaemia in oncology - Update 2003. Bull Cancer 2004; 91: 179-88.